Stent fractures after superficial femoral artery stenting: Risk factors and impact on patency

Journal of Endovascular Therapy

Volumn 22, Issue 3, 2015, Pages 319-326

  Lin, Yuting ^a   Tang, Xiao ^a   Fu, Weiguo ^a   Kovach, Richard ^b   George, Jon C ^b   Guo, Daqiao ^a  

^a FUDAN UNIVERSITY   (China)

^b DEBORAH HEART AND LUNG CENTER   (United States)

Author keywords

Chronic total occlusion; Complication; Fracture; Overlapping stents; Patency; Stenosis; Stent; Superficial femoral artery

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL;

AGED; ANGIOGRAPHY; ARTERY CALCIFICATION; ARTERY OCCLUSION; ARTICLE; CLINICAL ASSESSMENT TOOL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONFIDENCE INTERVAL; DIGITAL SUBTRACTION ANGIOGRAPHY; DOPPLER FLOWMETRY; ECHOGRAPHY; FEMALE; GRAFT PATENCY; HAZARD RATIO; HUMAN; HYPERLIPIDEMIA; LEG; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PEAK SYSTOLIC VELOCITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STENT FRACTURE; SUPERFICIAL FEMORAL ARTERY; SUPERFICIAL FEMORAL ARTERY STENOSIS; SUPERFICIAL FEMORAL ARTERY STENT; TRANSATLANTIC INTER SOCIETY CONSENSUS II; ADVERSE EFFECTS; CHRONIC DISEASE; DEVICES; DUPLEX DOPPLER ULTRASONOGRAPHY; ENDOVASCULAR SURGERY; FACTUAL DATABASE; FEMORAL ARTERY; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; PROPORTIONAL HAZARDS MODEL; PROSTHESIS DESIGN; PROSTHESIS FAILURE; RADIOGRAPHY; STENT; TIME FACTOR; TREATMENT OUTCOME; VASCULAR CALCIFICATION; VASCULAR PATENCY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CHRONIC DISEASE; DATABASES, FACTUAL; ENDOVASCULAR PROCEDURES; FEMALE; FEMORAL ARTERY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERIPHERAL ARTERIAL DISEASE; PROPORTIONAL HAZARDS MODELS; PROSTHESIS DESIGN; PROSTHESIS FAILURE; RETROSPECTIVE STUDIES; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, DUPLEX; VASCULAR CALCIFICATION; VASCULAR PATENCY;

EID: 84939785278     PISSN: 15266028     EISSN: 15451550     Source Type: Journal    
DOI: 10.1177/1526602815580783     Document Type: Article

References (19)

1. Lugmayr HF, Holzer H, Kastner M, et al. Treatment of complex arteriosclerotic lesions with nitinol stents in the superficial femoral and popliteal arteries: a midterm followup. Radiology. 2002;222:37-43.
2. Vogel TR, Shindelman LE, Nackman GB, et al. Efficacious use of nitinol stents in the femoral and popliteal arteries. J Vasc Surg. 2003;38:1178-1184.
3. Duda SH, Pusich B, Richter G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation. 2002;106:1505-1509.
4. Iida O, Nanto S, Uematsu M, et al. Influence of stent fracture on the long-term patency in the femoropopliteal artery: experience of 4 years. JACC Cardiovasc Interv. 2009;2: 665-671.
5. Duda SH, Bosiers M, Pusich B, et al. Endovascular treatment of peripheral artery disease with expanded PTFE-covered nitinol stents: interim analysis from a prospective controlled study. Cardiovasc Intervent Radiol. 2002;25:413-418.
6. Lewitton S, Babaev A. Superficial femoral artery stent fracture that led to perforation, hematoma and deep venous thrombosis. J Invasive Cardiol. 2008;20:479-481.
7. Tosaka A, Soga Y, Iida O, et al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59:16-23.
8. Jaff M, Dake M, Pompa J, et al. Standardized evaluation and reporting of stent fractures in clinical trials of noncoronary devices. Catheter Cardiovasc Interv. 2007;70:460-462.
9. Davaine JM, Quérat J, Guyomarch B, et al. Incidence and the clinical impact of stent fractures after primary stenting for TASC C and D femoropopliteal lesions at 1 year. Eur J Vasc Endovasc Surg. 2013;46:201-212.
10. Kronenberg F, Mündle M, Längle M, et al. Prevalence and progression of peripheral arterial calcifications in patients with ESRD. Am J Kidney Dis. 2003;41:140-148.
11. Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 2014;83:E212-E220.
12. Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45:312-315.
13. Iida O, Soga Y, Hirano K, et al. Retrospective multicentre analysis of S.M.A.R.T. vs. Luminexx nitinol stent implantation for superficial femoral artery lesions (REAL SL) Registry. 5 years' experience. Circ J. 2011;75:421-427.
14. Matsumura JS, Yamanouchi D, Goldstein JA, et al. The United States StuDy for Evaluating Endovascular Treatments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By using the Protégé EverfLex NitInol Stent System II (DURABILITY II). J Vasc Surg. 2013;58:73-83.e1.
15. Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701-710.
16. Cheng CP, Wilson NM, Hallett RL, et al. In vivo MR angiographic quantification of axial and twisting deformations of the superficial femoral artery resulting from maximum hip and knee flexion. J Vasc Interv Radiol. 2006;17: 979-987.
17. Soucie JM, Wang C, Forsyth A, et al. Range of motion measurements: reference values and a database for comparison studies. Haemophilia. 2011;17:500-507.
18. Higashiura W, Kubota Y, Sakaguchi S, et al. Prevalence, factors, and clinical impact of self-expanding stent fractures following iliac artery stenting. J Vasc Surg. 2009;49:645-652.
19. Krankenberg H, Schlüter M, Steinkamp HJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the Femoral Artery Stenting Trial (FAST). Circulation. 2007;116: 285-292.